Loading...
| A10308 | Pages: NA | Jul 2022 | 627 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Specimen Validity Testing Market
Request Now !Specimen validity tests are carried out on a urine drug screen specimen which helps in the process of substitution, dilution and, adulteration.
Substitution- Substitution involves the process of separating water or salt from the specimen and is recognizing by extreme creatinine and any other specific results.
Dilution- In this process, if the drug in the urine is diluted due to the excess of water present in the body below the minimal value, the results can show a false negative.
Adulteration-A contaminant might be added in the sample to affect the testing reagents negatively.
Specimen validity tests are very essential when it comes to urine drug tests. This test supplies disorder analysts with important details about the reliability and accuracy of drug test results, after examining if the specimen received is a valid human urine specimen.
Indicators used during a specimen validity test include:
1) Creatinine
2) Specific Gravity
3) pH
4) Dilute Specimens
5) Substituted Specimen
6) Adulterated Specimen
7) Invalid Specimen
Market scope and structure analysis:
Report Metric | Details |
Market size available for years | 2019–2027 |
Base year considered | 2019 |
Forecast period | 2020–2027 |
Forecast units | Value (USD) |
Segments covered | Product and Services, Type, End users, and Region |
Regions covered | North America (U.S. and Canada), Europe (Germany, UK, France, and the Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of LATAM) and The Middle East and Africa. |
Companies covered | Major players analyzed include Thermo Fisher, Sciteck, American Bio Medica Corporation, Alere, Express Diagnostics, Premier Biotech, LabCorp, Quest Diagnostics, Alere Toxicology, ACM Global Laboratories, Clinical Reference Laboratory (CRL), SureHire, and CannAmm. |
COVID-19 scenario analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
Owing to such factors, COVID 19 is expected to have a significant impact on the Specimen Validity Testing market.
Increasing consumption of illegal drugs is raising globally, stringent regulations and commandments in drug screening and governments investing to control the drug abuse are propelling the global market during the specimen validity testing. There has also been a considerable amount of rise in the number of laboratories for the screening of drugs and also increasing R & D programs. Additionally, there has been a high demand for carrying out the presumptive tests as the drug abuse population keeps rising. Government support is encouraging the research programs and new opportunities are propelling the market.
Urine drug screening is also helping to upgrade the safety of the patients in the hospital, Awareness is increasing but various government initiatives about the tests and the initiatives are helping in getting acceptance from the population globally. Partnerships and acquisitions of various major key manufactures are also affecting the specimen validity testing market.
On the other hand, emergence and awareness of new and alternative methods are the major challenges faced in the specimen validity testing market.
On May 21st, 2020, Labs@Home is introducing new outpatient management for the transplants of kidneys during the pandemic period.
On April 15th, 2020, Abbott has started a new blood test for the detection of antibodies which indicates if the patient is affected with the novel coronavirus.
Drug screening laboratories, workplaces, criminal justice, and agencies for law enforcement, drug rehabilitation centers, pain management centers, are the major end-users for the specimen validity testing market. Amongst them, workplaces and drug screening laboratories are the biggest consumers.
Key segments covered:
Segments | Sub-segments |
Product & Service |
|
Type |
|
End- User |
|
Regions |
|
Key benefits of the report:
Questions answered in the Specimen Validity Testing Market research report:
Key Market Segments
| Segments | Sub-segments |
|---|---|
| By Product & Service |
|
| By Type |
|
| By End- User |
|
| By Region |
|
Key Market Players
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
